Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. (NVUS) on April 30, 2019. The registrant is a Delaware corporation focused on developing treatments for acute otitis media. The report details a material definitive agreement entered into on April 30, 2019, which closed on May 2, 2019.
Key Financial Metrics and Transaction Details
- Offering Size: 3,449,112 shares of Common Stock sold at $3.095 per share.
- Gross Proceeds: Approximately $10.67 million (calculated from share count and price).
- Net Proceeds: Approximately $9.8 million after deducting placement agent fees and expenses.
- Warrant Structure:
- Series A Warrants: 18-month term, exercisable immediately at $4.00 per share for 100% of shares sold.
- Series B Warrants: 5-year term, exercisable at $4.00 per share only upon exercise of Series A Warrants.
- Placement Agent Fees: 7.0% cash fee on gross proceeds plus 1.0% management fee, plus expense allowances and warrants for 5.0% of shares sold.
Material Changes and Use of Proceeds
The primary material change is the capital raise described above. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for prior periods as this is a current report on a specific transaction rather than a periodic financial statement. The net proceeds are designated to:
- Expand the ongoing Phase 2a clinical trial in acute otitis media from 50 to approximately 140 patients.
- Provide working capital and other general corporate purposes.
Outlook, Risks, and Contingencies
Management Commentary: The company intends to utilize the capital to accelerate clinical development. H.C. Wainwright & Co., LLC acted as the exclusive placement agent.
Risks and Contingencies:
- Registration: The Warrants and underlying shares were sold unregistered under Section 4(a)(2) and Rule 506. The Company agreed to file a registration statement for the resale of Warrant Shares within 45 calendar days of April 30, 2019.
- Dilution: The issuance of common stock and warrants will result in dilution to existing shareholders.
Investor Verification Checklist
- Verify the closing date of May 2, 2019, and confirm receipt of the $9.8 million net proceeds.
- Review the filed registration statement for the resale of Warrant Shares to ensure it was filed within the 45-day deadline.
- Monitor the progress of the Phase 2a clinical trial expansion to 140 patients.
- Assess the potential dilution impact from the 3,449,112 shares sold plus the 172,456 Placement Agent Warrants and investor Warrants.